#USA #Carlsbad #Field Medical #PFA #HRX 2026

Introduction

Field Medical, Inc. has recently made headlines by publishing significant findings from its first-in-human trial, Field PULSE. Featured in JACC: Clinical Electrophysiology, these results reveal an impressive 12-month follow-up data showcasing a 94.2% durability of pulmonary vein isolation (PVI) prompted by an optimized waveform. This announcement coincides with its presentation at the HRX Live 2026 conference, marking a notable advancement in the treatment of complex cardiac arrhythmias.

The Technology and Trial

The core of Field Medical's innovation lies within its high-voltage focal pulsed field ablation (PFA) technology, designed to efficiently treat complex arrhythmias. The FieldForce™ system serves as the backbone of this approach, initially geared toward ventricular issues where precise depth and control are paramount. With the Field PULSE trial, the focus has shifted to the atrium, introducing a protocol that enables quick, point-by-point ablation in under one second, which the company terms as "instant ablation."

This trial has established a proof-of-concept for this novel technique, demonstrating a median procedure time of just 13 minutes for the PVI, with some instances recorded at a mere 7.7 minutes. Such efficiency minimizes patient time under catheter maintenance, enhancing overall safety and comfort.

Key Clinical Outcomes

Among the groundbreaking results:

• - Procedural Efficiency: The focal PFA technique exhibited remarkable procedural efficiency, achieving quick ablation cycles with minimal downtime.
• - Sustained Isolation: Participants experienced a durable PVI success rate of 94.2% per vein, a notable improvement throughout the trial as the waveform technology evolved.
• - Extended Flexibility: The study also highlighted the versatility of the system, with 49% of patients receiving additional ablation targeted at non-pulmonary vein sites.
• - Safety Profile: The trial reported no major safety events, assuring the technology’s reliability in clinical settings.
• - Atrial Fibrillation Recurrence: Impressively, 80% of subjects showed no recurrence of atrial fibrillation after a year post-procedure using the optimized waveform.

Dr. Vivek Reddy, the trial's co-investigator and lead author, expressed optimism about the findings. He noted, The Field PULSE study demonstrates the feasibility of true instant focal PFA. Delivering the full dose in under 200 milliseconds reduces the necessity for prolonged catheter maintenance, all while maintaining flexibility in point-by-point ablation.

Clinical Validation and Future Implications

These findings from the Field PULSE trial contribute greatly to the body of peer-reviewed literature on cardiac interventions, augmenting previous studies including Field Medical’s VCAS trial results published in Circulation in 2025. The research collectively confirms the efficacy and adaptability of the FieldForce architecture in treating both ventricular and atrial substrates. As Dr. Mark A. Turco, CEO of Field Medical, stated, “This growing data set illustrates the potential breadth of applications using high-voltage PFA. We aim to refine our techniques continually to address the diverse needs arising in electrophysiology.”

The pivotal nature of these results paves the way for expanded clinical development. This technology not only reflects an essential advancement in cardiac ablation but also promises improvements in patient outcomes on a broader scale.

Conclusion

As Field Medical progresses with its clinical agenda, the implications of the Field PULSE findings shine a light on the future of arrhythmia treatments. Insights gained will guide the next steps in refining this innovative technology, envisioning a time when patients can benefit from more effective, faster, and safer cardiac procedures.

For additional insights and updates, visit Field Medical's official website.